Testing adding cemiplimab to chemo before surgery for sinus cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps treat sinonasal squamous cell carcinoma. The goal is to see if this combination reduces tumors more effectively than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of squamous cell carcinoma that started in the sinuses or nasal cavity.
- Your tumor must be a certain size (at least 1 cm on a CT or MRI scan) and rated as T3, T4a, or select T4b.
- You cannot have cancer that has spread to distant parts of the body, but spread to neck lymph nodes is allowed.
- You must be 18 years or older.
- Your overall health must be reasonably good (able to care for yourself and up and about more than half the day).
- Your heart function must be stable (New York Heart Association Class II or better).
- You must be willing to use effective birth control during and for 6 months after treatment, if applicable.
- Your insurance or other payment must cover the standard chemotherapy drugs used in this study (paclitaxel and carboplatin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
This trial tests whether combining chemotherapy with two immunotherapy drugs (PD-1 inhibitors) before surgery can improve outcomes for patients with advanced sinonasal carcinoma. It aims to shrink the tumor before removal.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This Phase 2 study tests a treatment plan that combines immunotherapy with chemotherapy and chemoradiation for advanced squamous cell cancer in the nasal cavity or sinuses. It aims to improve cancer control in people who are newly diagnosed and have not had prior treatment for this cancer.
Hear when a new Stage III Sinonasal Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.